Cadence Capital Management’s Puma Biotechnology PBYI Stock Holding History

Cadence Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$171K	Sell	16,927 -54,252	-76%	-$552K	0.04%	273
2020 Q2	$742K	Buy	+71,179	New	+$737K	0.11%	272
2017 Q3	–	Sell	-7,790	Closed	-$681K	–	705
2017 Q2	$681K	Buy	+7,790	New	+$436K	0.05%	446
2015 Q2	–	Sell	-1,760	Closed	-$416K	–	649
2015 Q1	$416K	Buy	+1,760	New	+$376K	0.03%	529
2014 Q4	–	Sell	-2,680	Closed	-$639K	–	642
2014 Q3	$639K	Buy	+2,680	New	+$550K	0.03%	467
2014 Q1	–	Sell	-5,000	Closed	-$518K	–	645
2013 Q4	$518K	Buy	+5,000	New	+$293K	0.02%	536

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Cadence Capital Management's PBYI Position: Q3 2020 in Review

Cadence Capital Management reduced its Puma Biotechnology (PBYI) stake by 76% in Q3 2020, selling an estimated $552K and leaving 16,927 shares worth $171K. The position accounts for 0.04% of the portfolio, ranked #273.

Cadence Capital Management first reported a position in PBYI in Q4 2013 and has held it in 6 quarters since. The position peaked at $742K in Q2 2020. 128 funds tracked by Wall St. Rank hold PBYI as of Q3 2020.

Cadence Capital Management held 16,927 shares of Puma Biotechnology worth $171K as of Q3 2020.
Cadence Capital Management sold 54,252 Puma Biotechnology shares in Q3 2020, an estimated $552K.
Puma Biotechnology made up 0.04% of Cadence Capital Management's portfolio in Q3 2020, its #273 holding.
Cadence Capital Management first reported a position in Puma Biotechnology in Q4 2013 and has held it in 6 quarters since.
Cadence Capital Management's Puma Biotechnology position peaked at $742K in Q2 2020.
128 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.